Reliant Pharma blueprints $400M IPO

On Friday Reliant Pharmaceuticals launched a bid to raise as much as $400 million in an IPO. About half of that could go to pay off debt and the rest could be used for a variety of corporate expenses, including new acquisitions. Liberty Corner, NJ-based Reliant has four cardiovascular therapies on the market in the U.S. Reliant's development strategy focuses on in-licensing mid- to late-stage products in order to reduce the risk of development. The company was founded in 1999.

- here's the release on the IPO

Related Article:
Reliant pulls IPO. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.